Debate on Spinal Fusion Surgeries Continues
Carragee is hopeful about the broad ramifications of the Medtronic plan, but he also has concerns about the study of the spinal fusion product.
"There have been many years of repeated and categorical denials [of] associated complications by paid consultants or other surgeons with financial ties to the company," Carragee says. "Yale can get all the FDA reports in existence but because of the history of denying associated problems, they will have only the tip of the iceberg."
Harlan Krumholz, MD, a professor of cardiology and investigative medicine at Yale Medical School, will lead the independent review.
Krumholz's strategy "is to ask the right question and pick the right measurement – and it can get the right answer," Yale Medical School's Web site notes. Forbes Magazine also has called Krumholz "The Most Powerful Doctor You Never Heard Of." In the spinal surgery field, Krumholz's name will certainly become more known. Whether he pushes beyond the "tip of the iceberg" as Carragee fears, is not yet known.
Joe Cantlupe is a senior editor with HealthLeaders Media Online.
- FDA hopes hospitals will switch to newly regulated pharmacies
- CMS Sets 2014 Pay Rates for Hospital Outpatient and Physician Services
- New G-Codes to Pay Doctors for Broad Array of Non-Face-to-Face Care
- States Rejecting Medicaid Expansion Forgo Billions in Federal Funds
- Why You Should Involve Patients in Nursing Handoffs
- Not-for-Profit Hospitals Find Opportunity Amid Uncertainty
- Substance Abuse Resurfaces Among Anesthesiologists in Training
- Douglas Hawthorne—A Chance to Do Something Big
- Safety Net Executives Renew Call to Preserve DSH Payments
- The Most Polarizing Topics in Healthcare IT